Cardiol Therapeutics (CRDL) to Release Quarterly Earnings on Tuesday

Cardiol Therapeutics (NASDAQ:CRDL) is anticipated to release its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Cardiol Therapeutics Price Performance

Shares of NASDAQ:CRDL opened at $1.25 on Friday. The firm has a market cap of $139.68 million, a price-to-earnings ratio of -4.17 and a beta of 1.02. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $1.59. The company has a current ratio of 3.89, a quick ratio of 3.89 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $1.04.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CRDL. upgraded Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cardiol Therapeutics presently has an average rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Security National Bank of Sioux City Iowa IA bought a new position in Cardiol Therapeutics in the 4th quarter worth approximately $31,000. Simplex Trading LLC boosted its position in shares of Cardiol Therapeutics by 96.9% in the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock valued at $31,000 after acquiring an additional 15,842 shares during the period. Bank of America Corp DE grew its stake in shares of Cardiol Therapeutics by 136.2% in the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after acquiring an additional 15,255 shares during the last quarter. Susquehanna International Group LLP increased its position in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the period. Finally, Virtu Financial LLC acquired a new position in Cardiol Therapeutics during the 3rd quarter valued at $154,000. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.